Semaglutide as an active ingredient is FDA-approved under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management)
Even clear, colorless solutions may have diminished therapeutic activity, which is why adhering to expiration dates and proper storage conditions is essential for ensuring medication safety and effectiveness
This analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for GLP-1s
Example plan pricing screen reviewed on February 19, 2026
Clinical Practice Guidelines for Obesity
4 reported observational data from Shanghai Sixth Peoples Hospital, China, showing that, with adequate treatment duration, GLP-1 agonists may have disease-modifying effects in patients with KOA with comorbid Type 2 diabetes, potentially mediated by weight loss